Key result
Class III antiarrhythmics dofetilide and amiodarone robustly inhibit SARS-CoV-2 ORF 3a currents in vitro.
Why the study?
COVID-19 is linked to cardiac arrhythmias, and the SARS-CoV-2 ORF 3a protein encodes an ion channel that may contribute to these complications.
Do antiarrhythmic drugs inhibit SARS-CoV-2 ORF 3a-mediated currents in preclinical models?
Do antiarrhythmic drugs inhibit SARS-CoV-2 ORF 3a-mediated currents in preclinical models?
Answers are grounded in this paper and cite their sources.
Class III antiarrhythmic drugs, particularly dofetilide and amiodarone, robustly inhibit SARS-CoV-2 ORF 3a-mediated currents, offering a potential pharmacological target for COVID-19-associated arrhythmias.
AIMS: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been linked to cardiovascular complications, notably cardiac arrhythmias. The open reading frame (ORF) 3a of the coronavirus genome encodes for a transmembrane protein that can function as an ion channel. The aim of this study was to investigate the role of the SARS-CoV-2 ORF 3a protein in COVID-19-associated arrhythmias and its potential as a pharmacological target. METHODS AND RESULTS: Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) and cultured human fibroblasts were infected with SARS-CoV-2. Subsequent immunoblotting assays revealed the expression of ORF 3a protein in hiPSC-CM but not in fibroblasts. After intracytoplasmic injection of RNA encoding ORF 3a proteins into Xenopus laevis oocytes, macroscopic outward currents could be measured. While class I, II, and IV antiarrhythmic drugs showed minor effects on ORF 3a-mediated currents, a robust inhibition was detected after application of class III antiarrhythmics. The strongest effects were observed with dofetilide and amiodarone. Finally, molecular docking simulations and mutagenesis studies identified key amino acid residues involved in drug binding. CONCLUSION: Class III antiarrhythmic drugs are potential inhibitors of ORF 3a-mediated currents, offering new options for the treatment of COVID-19-related cardiac complications.
No takes yet. Share an insight, caveat, or question.
Wiedmann et al. (2024) studied COVID-19-associated arrhythmias. Class III antiarrhythmic drugs vs. Class I, II, and IV antiarrhythmic drugs was evaluated on ORF 3a-mediated macroscopic outward currents. Class III antiarrhythmic drugs, particularly dofetilide and amiodarone, robustly inhibited SARS-CoV-2 ORF 3a-mediated currents in vitro.
Synapse has enriched 10 related papers. Consider them for comparative context: